Once E3 tags CYP17A1, the cell uses its proteasome to break down the enzyme entirely. One major advantage of PROTACs is that ...

VANCOUVER, BC / ACCESS Newswire / November 18, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it is ...

A new word is making the rounds in the business press: "anti-involution." In recent years, Chinese companies have built ...

Two research teams 3000 miles apart discover a common bacterium triggering chronic gastrointestinal pain — while developing a ...

When a bioactive molecule occurs in nature at trace levels, traditional extraction often means sifting through mountains of ...

George Town, Cayman Islands, November 17th, 2025, FinanceWireCV5 Capital, the leading institutional platform for digital ...

OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer.

By fusing enzyme fragments to antibodies, researchers from Institute of Science Tokyo, Japan, developed an innovative enzyme ...

Researchers at the University created an AI model called EZSpecificity to test how certain enzymes and substrates bind to ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

Cognision, provider of advanced neurobiomarker technology, announces its partnership with Kynexis to utilize the COGNISION(R) System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with ...

Cognision, provider of advanced neurobiomarker technology, announces its partnership with Kynexis to utilize the COGNISION® System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with ...